Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
about
Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implicationsNew and emerging targeted therapies for cystic fibrosisTargeted therapies to improve CFTR function in cystic fibrosisCFTR Modulators: Shedding Light on Precision Medicine for Cystic FibrosisCurrent and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its SymptomsPediatric Pulmonology year in review 2015: Part 4.Harnessing public domain data to discover and validate therapeutic targets.In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.Hallmarks of therapeutic management of the cystic fibrosis functional landscape.Cardiorespiratory and sensory responses to exercise in adults with mild cystic fibrosis.The magnitude of ivacaftor effects on fluid secretion via R117H-CFTR channels: Human in vivo measurementsFrom CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations.Pilot evaluation of ivacaftor for chronic bronchitis.Cystic fibrosis: a model system for precision medicine.Therapeutic Approaches to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis.Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic FibrosisSearching for a cure for cystic fibrosis. A 25-year quest in a nutshell.Biomarkers for cystic fibrosis drug development.Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770A safety evaluation of ivacaftor for the treatment of cystic fibrosis.New drug developments in the management of cystic fibrosis lung disease.New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.Individualized medicine using intestinal responses to CFTR potentiators and correctors.Cystic fibrosis: a clinical view.The use of ivacaftor in CFTR mutations resulting in residual functioning protein.On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator.Cas9/gRNA targeted excision of cystic fibrosis-causing deep-intronic splicing mutations restores normal splicing of CFTR mRNA.CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on Ivacaftor.Highlights from the 2015 North American Cystic Fibrosis Conference.Breathing Easier: A Well-tolerated Corrector for F508del.Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR.Toward inclusive therapy with CFTR modulators: Progress and challenges.Early Intervention of Cystic Fibrosis Pulmonary Exacerbations Based on Home Monitoring. eICE through the Looking Glass.The Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Ivacaftor Augments Mucociliary Clearance Abrogating Cystic Fibrosis Transmembrane Conductance Regulator Inhibition by Cigarette Smoke.Personalized Medicine in CF: From Modulator Development to Therapy for Cystic Fibrosis Patients with Rare CFTR Mutations.Transformative therapies for rare CFTR missense alleles.Therapeutic benefit observed with the CFTR potentiator, ivacaftor, in a CF patient homozygous for the W1282X CFTR nonsense mutation.Cystic Fibrosis: The Dawn of a New Therapeutic Era.Chronic β2AR stimulation limits CFTR activation in human airway epithelia.Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study.
P2860
Q26747065-FC6FCAF4-9E0A-4F0A-9591-11987BA4C383Q26749278-A2A666E4-6E34-469F-802B-2B3A51E9E88CQ26781441-586B7528-ACDE-4062-BF2D-8BF297627460Q28073996-6C0796E8-6466-47DC-AF02-41048704CC70Q28077411-466EC437-D220-4D00-B7CD-56A33C191A2DQ30250335-001D2347-2351-4889-A0B8-115864976A35Q30491667-619ADB33-2B0D-4760-A909-17B1C4BFAB66Q33769791-239FA41F-E520-4DD2-8F38-5784BBD96AC8Q36279553-E4F008B3-A6BB-4E58-A969-72C506034F1CQ36345895-3F5C5E2A-4FE8-4A53-AC6B-9D77A92D6184Q36349707-F4586C47-5BA5-40E4-A5A2-DA9DD3141917Q36574664-2B0B2570-98BD-43E2-9890-1781155D65B9Q37028545-245D02CE-B2F9-4F3F-92E4-ECA2CC0D437CQ37097931-8FC19AFD-88E0-4FDB-980B-6F98C102B323Q37241561-A7C99118-28B9-4308-BCE9-C3A69F12DBA4Q37241563-4A5D13D0-8014-4721-9CBA-7F9FB6036719Q38633196-80B52D71-0116-459E-B1F3-CC3D86B50200Q38755600-2FFAA7B7-0538-4EE4-8F46-EE5479DBE506Q38758711-6F669230-7498-48A1-A2BF-84B35703252AQ38770171-0F516148-AE04-42C3-9E58-DB5D0B18EADFQ38790382-1EC319FC-0A7B-4DE5-9F5E-1B3B779CB278Q38836754-8091CFD2-E477-4DC5-AEEF-87ADC68922A3Q38962735-1D9E7F82-B895-42E3-B8B6-F9CDFBB1752DQ38973292-D2495C56-2D3E-48C4-874F-F487610DF324Q39216570-65C73305-6CE2-415B-9A8C-24C8C3A60321Q40023091-41275B97-9C65-4385-92FC-BEB9FC40B665Q41593485-F32D68DD-F099-4C1B-BFD3-2B5656927E97Q41641680-73352715-261D-417E-AAD6-C7B9A837D50AQ45294315-9C98F5B4-993C-4B1D-99BF-D4EA3319030EQ47739415-43A4EBCF-8D3A-4A88-9DD8-212D0C477B5FQ47767733-2EF1D5FD-18D7-451E-849E-B66B3060CC77Q47842086-5915D583-6A2E-4E78-9787-A6054160FFCBQ48144242-92A7855F-BD82-473B-8526-AC7250228C88Q49073386-8EBB643E-F552-4E42-808B-138860EFA2E3Q49917915-E57D69F3-8F18-4F8C-BA2B-BC2D93F7F374Q50069400-0D562BEB-77AA-4D4B-818B-1E7688C87948Q50485119-98F8DC2B-0D7D-48A7-B464-ADD5A0FA6E87Q51424428-402B8034-23C8-4AC6-A489-B6544941D26FQ51749305-AE161E22-CC2E-4D3E-AB3E-1A80026687ADQ52715682-B0F576FD-DCD8-47E7-9D71-21482BFD4EC0
P2860
Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Efficacy and safety of ivacaft ...... , randomised controlled trial.
@ast
Efficacy and safety of ivacaft ...... , randomised controlled trial.
@en
type
label
Efficacy and safety of ivacaft ...... , randomised controlled trial.
@ast
Efficacy and safety of ivacaft ...... , randomised controlled trial.
@en
prefLabel
Efficacy and safety of ivacaft ...... , randomised controlled trial.
@ast
Efficacy and safety of ivacaft ...... , randomised controlled trial.
@en
P2093
P2860
P1476
Efficacy and safety of ivacaft ...... , randomised controlled trial.
@en
P2093
Mark Higgins
Patrick A Flume
Richard B Moss
Ronald C Rubenstein
Steven M Rowe
Susanna A McColley
VX11-770-110 (KONDUCT) Study Group
P2860
P304
P356
10.1016/S2213-2600(15)00201-5
P577
2015-06-09T00:00:00Z